Actively separated microneedle patch for sustained-release of growth hormone to treat growth hormone deficiency.
10.1016/j.apsb.2022.04.015
- Author:
Li YANG
1
;
Qingyun LIU
1
;
Xinhui WANG
1
;
Nansha GAO
1
;
Xiuzhen LI
2
;
Hongzhong CHEN
1
;
Lin MEI
1
;
Xiaowei ZENG
1
Author Information
1. Institute of Pharmaceutics, School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China.
2. Department of Genetics and Endocrinology, Guangzhou Women and Children's Medical Center, Guangzhou 510623, China.
- Publication Type:Journal Article
- Keywords:
Actively separated;
Growth hormone;
Growth hormone deficiency;
Long-acting GH;
Microneedle;
Self-administration;
Silk protein;
Sustained-release
- From:
Acta Pharmaceutica Sinica B
2023;13(1):344-358
- CountryChina
- Language:English
-
Abstract:
Growth hormone deficiency (GHD) has become a serious healthcare burden, and presents a huge impact on the physical and mental health of patients. Here, we developed an actively separated microneedle patch (PAA/NaHCO3-Silk MN) based on silk protein for sustained release of recombinant human growth hormone (rhGH). Silk protein, as a friendly carrier material for proteins, could be constructed in mild full-water conditions and ensure the activity of rhGH. After manually pressing PAA/NaHCO3-Silk MN patch to skin for 1 min, active separation is achieved by absorbing the interstitial fluid (ISF) to trigger HCO3 ‒ in the active backing layer to produce carbon dioxide gas (CO2). In rats, the MN patch could maintain the sustained release of rhGH for more than 7 days, and produce similar effects as daily subcutaneous (S.C.) injections of rhGH in promoting height and weight with well tolerated. Moreover, the PAA/NaHCO3-Silk MN patch with the potential of painless self-administration, does not require cold chain transportation and storage possess great economic benefits. Overall, the PAA/NaHCO3-Silk MN patch can significantly improve patient compliance and increase the availability of drugs, meet current unmet clinical needs, improve clinical treatment effects of GHD patients.
